- Home
- RLAY vs NKX Comparison
RLAY vs NKX Comparison
Compare RLAY & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- NKX
- Stock Information
- Founded
- RLAY 2015
- NKX 2002
- Country
- RLAY United States
- NKX United States
- Employees
- RLAY N/A
- NKX N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- NKX Finance/Investors Services
- Sector
- RLAY Health Care
- NKX Finance
- Exchange
- RLAY Nasdaq
- NKX Nasdaq
- Market Cap
- RLAY 490.3M
- NKX 581.2M
- IPO Year
- RLAY 2020
- NKX N/A
- Fundamental
- Price
- RLAY $3.13
- NKX $11.77
- Analyst Decision
- RLAY Strong Buy
- NKX
- Analyst Count
- RLAY 11
- NKX 0
- Target Price
- RLAY $18.40
- NKX N/A
- AVG Volume (30 Days)
- RLAY 2.2M
- NKX 109.3K
- Earning Date
- RLAY 05-05-2025
- NKX 01-01-0001
- Dividend Yield
- RLAY N/A
- NKX 4.37%
- EPS Growth
- RLAY N/A
- NKX N/A
- EPS
- RLAY N/A
- NKX N/A
- Revenue
- RLAY $7,679,000.00
- NKX N/A
- Revenue This Year
- RLAY N/A
- NKX N/A
- Revenue Next Year
- RLAY $169.23
- NKX N/A
- P/E Ratio
- RLAY N/A
- NKX N/A
- Revenue Growth
- RLAY N/A
- NKX N/A
- 52 Week Low
- RLAY $1.78
- NKX $9.78
- 52 Week High
- RLAY $10.72
- NKX $12.00
- Technical
- Relative Strength Index (RSI)
- RLAY 50.08
- NKX 36.50
- Support Level
- RLAY $2.75
- NKX $11.76
- Resistance Level
- RLAY $3.10
- NKX $11.93
- Average True Range (ATR)
- RLAY 0.20
- NKX 0.08
- MACD
- RLAY 0.01
- NKX -0.02
- Stochastic Oscillator
- RLAY 58.16
- NKX 11.11
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.